KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Income from Continuing Operations (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of Income from Continuing Operations data on record, last reported at 49573000.0 in Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 339.0% year-over-year to 49573000.0; the TTM value through Dec 2025 reached 127933000.0, up 273.17%, while the annual FY2025 figure was 127933000.0, 273.17% up from the prior year.
  • Income from Continuing Operations reached 49573000.0 in Q4 2025 per AMRX's latest filing, up from 18132000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 49573000.0 in Q4 2025 and bottomed at 240081000.0 in Q2 2022.
  • Average Income from Continuing Operations over 5 years is 11461300.0, with a median of 4668500.0 recorded in 2022.
  • The widest YoY moves for Income from Continuing Operations: up 1134.42% in 2023, down 1504.14% in 2023.
  • A 5-year view of Income from Continuing Operations shows it stood at 20418000.0 in 2021, then surged by 71.51% to 5817000.0 in 2022, then crashed by 1504.14% to 93313000.0 in 2023, then soared by 77.77% to 20742000.0 in 2024, then soared by 339.0% to 49573000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 49573000.0 in Q4 2025, 18132000.0 in Q3 2025, and 35610000.0 in Q2 2025.